Orthofix Medical Inc. ( OFIX) Stock. Should you Buy or Sell? $ 21.43
0.59 (2.68 %)
Orthofix Medical Inc. Analysis
Updated on 10-09-2022| Symbol | OFIX |
| Price | $21.43 |
| Beta | 1.015 |
| Volume Avg. | $113.11 thousand |
| Market Cap | $428.68 M |
| 52 Week Range | $19.32 - $41.17 |
Orthofix Medical Inc. opened the day at $21.43 which is +'2.68 % on yesterday's close. Orthofix Medical Inc. has a 52 week high of $41.17 and 52 week low of $19.32, which is a difference of $21.85. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $428.68 M and total net profit is $464479000 which means the company is trading at 0.92 times profit to market capitalization. Theoretically, if you were to buy Orthofix Medical Inc. for $428.68 M, it would take 15 years to get your money back. Orthofix Medical Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Orthofix Medical Inc. Stock Forecast - Is Orthofix Medical Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Buy | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -11.616 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -0.080 |
Valuing Orthofix Medical Inc.
| Price Book Value Ratio | 1.255 | Price To Book Ratio | 1.255 |
| Price To Sales Ratio | 0.929 | Price Earnings Ratio | -11.616 |
How liquid is Orthofix Medical Inc.
| Current Ratio | 3.147 |
| Quick Ratio | 1.684 |
Debt
| Debt Ratio | 0.259 | Debt Equity Ratio | 0.350 |
| Long Term Debt To Capitalization | 0.054 | Total Debt To Capitalization | 0.056 |
Latest news about Orthofix Medical Inc.
Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Alexa Huerta – Senior Director-Investor Relations Jon Serbousek – President and Chief Executive Officer Doug Rice – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Jeffrey Cohen – Ladenburg Jim Sidoti – Sidoti and Company Operator Hello, and a warm welcome to Orthofix Medical's Q2 2022 Earnings Call. My name is Melissa, and I'll be your operator today.
Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Jon Serbousek – Director, President and Chief Executive Officer Doug Rice – Chief Financial Officer Alexa Huerta – Senior Director of Investor Relations and Finance Conference Call Participants Mathew Blackman – Stifel Financial Corp. Jeffrey Cohen – Ladenburg Thalmann & Co. Inc. Jim Sidoti – Sidoti & Company, LLC Operator Good morning, everyone and welcome to today's Orthofix Medical First Quarter 2022 Earnings Conference Call. My name is Candice and I will be your moderator for today's call.
Orthofix (OFIX) delivered earnings and revenue surprises of -155.56% and 1.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
About Orthofix Medical Inc.
Description :
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
